lymphoma
Roche scores FDA approval for Polivy combo in diffuse large B-cell lymphoma
June 11, 2019Manufacturing and Production, Sales and Marketing Polivy, Roche, lymphoma, pharma
Roche is celebrating the decision taken by the FDA to approve its anti-CD79b antibody-drug conjugate Polivy (polatuzumab vedotin-piiq) in combination …
FDA first as agency expands label on Celgene’s Revlimid in previously treated follicular or marginal zone lymphoma
May 29, 2019Research and Development, Sales and Marketing Cancer, Celgene, FDA, Revlimid, lymphoma, pharma
Celgene has revealed that the FDA has expanded its authorised indications of Revlimid (lenalidomide) to include combination with a rituximab …
NICE recommend Takeda’s lymphoma treatment Adcetris
March 25, 2019Sales and Marketing Cancer, NICE, Takeda, UK, lymphoma, oncology, recommendation
Britain’s cost effectiveness body has recommended Takeda’s Adcetris (brentuximab vedotin) for adult patients with CD-30 positive advanced cutaneous T-cell lymphoma …
Novartis’ CAR-T therapy Kymriah gets NICE green light in diffuse large B-cell lymphoma
February 1, 2019Medical Communications, Sales and Marketing CAR-T, Cancer, Kymriah, NICE, Novartis, lymphoma, pharma
NICE has announced another momentous decision for lymphoma patients in England and Wales:, recommending Novartis’ chimeric antigen receptor T cell …
Epizyme shuts down failing lymphoma trial as FDA imposes clinical hold
August 3, 2018Medical Communications, Research and Development Epizyme, FDA, lymphoma, pharma, tazemetostat
Epizyme’s Q2 financial results have been derailed by the company’s decision to terminate further Phase 2 development of its lead …
Celgene’s Revlimid combo meets Phase 3 goal in relapsed/refractory indolent lymphoma
July 24, 2018Manufacturing and Production, Research and Development Celgene, Revlimid, lymphoma, pharma
Celgene has lifted the curtain on new Phase 3 data for its combo of Revlimid (lenalidomide) plus rituximab (R2) in …
Blood cancer patients over 75 are significantly underrepresented in clinical trials, study finds
December 13, 2017Research and Development FDA, blood cancer, leukaemia, lymphoma, myeloid leukaemia, pharma
The FDA’s first comprehensive analysis of clinical trial enrolment in older patients with blood cancers has revealed that the population …
New research reports first-ever response of central nervous tumour to CAR T therapy
August 29, 2017Manufacturing and Production, Research and Development CAR T, CAR-T, Cancer, life sciences, lymphoma, medicine, pharma, pharmaceuticals
Researchers at a General Hospital in Massachusetts has reported what they claim is the first response of a nervous system …
Roche antibody becomes first of its kind authorised for blood cancer
July 26, 2017Research and Development, Sales and Marketing CDF, Cancer, NICE, drugs, lymphoma, pharma, pharmaceutical Roche
NICE has announced its decision to make Roche’s Gazyvaro available via the Cancer Drugs Fund (CDF) in combination with chemotherapy …
Celltrion biosimilar proves effectiveness in lymphoma and rheumatoid arthritis
June 14, 2017Research and Development Cellltrion, Truxima, biosimilar, lymphoma, rheumatoid arthritis, rutiximab
Celltrion Healthcare has revealed new data which validates its biosimilar Truxima (CT-P10) as non-inferior to its reference product rituximab in …
Gamida Cell receives Breakthrough Therapy Designation from FDA
October 12, 2016Research and Development Breakthrough Therapy Designation, FDA, Gamida Cell, leukaemia, lymphoma
Gamida Cell have been granted a Breakthrough Therapy Designation for their NiCord drug. NiCord has already passed through Phase I …
$600m acquisition bolsters Celgene’s blood cancer portfolio
October 3, 2016Manufacturing and Production, Research and Development Celgene, EngMab, acquisition, lymphoma, multiple myeloma
Celgene has shelled out $600m for Swiss biotech EngMab in an effort to reinforce its blood cancer portfolio with a …
Phase III success for Takeda in lymphoma drug
August 1, 2016Manufacturing and Production, Research and Development Adcetris, Seattle Genetics, Takeda, lymphoma
Takeda Oncology and Seattle Generic have announced new Phase III data for trial drug, Adcetris (brentuximab vedotin), in patients with …
Celgene’s Revlimid fails to improve overall survival from lymphoma in Phase III trial
July 26, 2016Research and Development Celgene, Revlimid, lymphoma
Celgene has announced the publication of data from a Phase III trial investigating Revlimid (lenalidomide) in diffuse large B-cell lymphoma …
Roche’s lymphoma drug fails to beat rivals in Phase III trial
July 18, 2016Research and Development, Sales and Marketing Roche, lymphoma, phase III
Roche has announced that a Phase III trial evaluating Gazyva/Gazyvaro (obinutuzumab) in patients with previously untreated diffuse large B-cell lymphoma …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
